Q1 EPS Estimate for Context Therapeutics Reduced by Analyst

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Context Therapeutics in a report released on Tuesday, March 24th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at $0.08 EPS.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03).

A number of other research firms have also recently weighed in on CNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday. JonesTrading began coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Finally, Piper Sandler lifted their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Context Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $6.60.

Context Therapeutics Stock Performance

CNTX stock opened at $2.54 on Thursday. The stock’s 50 day moving average price is $2.46 and its 200 day moving average price is $1.61. The firm has a market cap of $233.38 million, a P/E ratio of -6.68 and a beta of 1.96. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.62.

Institutional Trading of Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Context Therapeutics during the 4th quarter valued at about $43,000. XTX Topco Ltd boosted its position in shares of Context Therapeutics by 858.8% in the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Context Therapeutics in the fourth quarter valued at approximately $68,000. Millennium Management LLC acquired a new position in Context Therapeutics during the fourth quarter worth approximately $3,824,000. Finally, Marshall Wace LLP increased its position in Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics News Roundup

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target for CNTX to $7.00, giving investors a higher valuation anchor that could support upside if clinical or commercial progress validates the view. Piper Sandler Raises Context Therapeutics (NASDAQ:CNTX) Price Target to $7.00
• Positive Sentiment: Guggenheim initiated (or reiterated) a Buy on CNTX, a bullish signal that can attract momentum buyers and institutional interest. Context Therapeutics (NASDAQ:CNTX) Earns Buy Rating from Guggenheim
• Positive Sentiment: D. Boral Capital also gave CNTX a Buy rating, adding to the cluster of bullish broker opinions that may support demand at current levels. Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from D. Boral Capital
• Neutral Sentiment: HC Wainwright’s report includes a long‑range projection of a modestly positive FY2030 EPS ($0.08), implying the firm expects potential profitability by the end of the decade — a distant, high‑uncertainty view. MarketBeat: Context Therapeutics analyst note summary
• Negative Sentiment: HC Wainwright (analyst E. Bodnar) cut multiple near‑term EPS estimates on March 24th — trimming Q1–Q4 2026 and lowering FY2026–FY2029 forecasts (FY2026 revised to -$0.60 from -$0.49; FY2027–FY2029 also materially lowered). Those downgrades signal weaker expected near‑term economics and drove downward pressure on the stock today. MarketBeat: HC Wainwright cuts Context Therapeutics EPS estimates

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.